Five-year outcomes of the Bi- versus Trimodular EndurantTM stent-graft in 100 patients with infrarenal abdominal aortic repair.

Susanne Kemmling, M. Wiedner, E. Stahlberg, M. Sieren, F. Jacob, J. Barkhausen, J. Goltz
{"title":"Five-year outcomes of the Bi- versus Trimodular EndurantTM stent-graft in 100 patients with infrarenal abdominal aortic repair.","authors":"Susanne Kemmling, M. Wiedner, E. Stahlberg, M. Sieren, F. Jacob, J. Barkhausen, J. Goltz","doi":"10.23736/S0021-9509.22.11947-6","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nRecent studies on the Endurant™ endografts mainly compared outcomes of the bimodular stent graft to other manufacturer's endografts or reported results for cases outside manufacturer's instructions for use (IFU), while data on the experience of standard endovascular aortic repair (EVAR) of infrarenal abdominal aortic aneurysms (AAA) inside manufacturer's IFU comparing the bi- with the trimodular device is limited.\n\n\nMETHODS\nInclusion criteria were 1) infrarenal aneurysms (>50 mm diameter) treated by EndurantTM II (END II) or EndurantTM IIs (END IIs) stent graft inside manufacturer's IFU 2) available CTA with 1 mm reconstruction of the entire aorta prior to intervention. Endpoints comparing the devices included technical success, 30d mortality, rate of complications (bleeding with conversion to open repair, stent graft stenosis/occlusion, acute distal embolism, infection or postprocedural necessity of dialysis), endoleaks and re-interventions (5-year follow-up). Aneurysm sac diameters were compared between baseline pre-interventional CTA and last post-interventional CTA.\n\n\nRESULTS\n100 patients (90% male, mean age 74y.) treated with END II (n=66) or END IIs (n=34) were included. Technical success was 99%. One procedure-related active bleeding occurred ending up in surgical conversion (END II n=1). 30d mortality was 0%. No initial type I/III endoleaks were present. Re-interventions were required in 19/100 (19%) of patients (END II n=10; END IIs n=9, p= 0.17). The outcome of EVAR including technical success, 30d mortality, rate of complications, endoleaks and re-interventions showed no significant differences comparing END II/IIs.\n\n\nCONCLUSIONS\nFive-year outcomes of EVAR show consistently safe and effective results for either END II or IIs device.","PeriodicalId":101333,"journal":{"name":"The Journal of cardiovascular surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of cardiovascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0021-9509.22.11947-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Recent studies on the Endurant™ endografts mainly compared outcomes of the bimodular stent graft to other manufacturer's endografts or reported results for cases outside manufacturer's instructions for use (IFU), while data on the experience of standard endovascular aortic repair (EVAR) of infrarenal abdominal aortic aneurysms (AAA) inside manufacturer's IFU comparing the bi- with the trimodular device is limited. METHODS Inclusion criteria were 1) infrarenal aneurysms (>50 mm diameter) treated by EndurantTM II (END II) or EndurantTM IIs (END IIs) stent graft inside manufacturer's IFU 2) available CTA with 1 mm reconstruction of the entire aorta prior to intervention. Endpoints comparing the devices included technical success, 30d mortality, rate of complications (bleeding with conversion to open repair, stent graft stenosis/occlusion, acute distal embolism, infection or postprocedural necessity of dialysis), endoleaks and re-interventions (5-year follow-up). Aneurysm sac diameters were compared between baseline pre-interventional CTA and last post-interventional CTA. RESULTS 100 patients (90% male, mean age 74y.) treated with END II (n=66) or END IIs (n=34) were included. Technical success was 99%. One procedure-related active bleeding occurred ending up in surgical conversion (END II n=1). 30d mortality was 0%. No initial type I/III endoleaks were present. Re-interventions were required in 19/100 (19%) of patients (END II n=10; END IIs n=9, p= 0.17). The outcome of EVAR including technical success, 30d mortality, rate of complications, endoleaks and re-interventions showed no significant differences comparing END II/IIs. CONCLUSIONS Five-year outcomes of EVAR show consistently safe and effective results for either END II or IIs device.
双模与三模endururttm支架在100例肾下腹主动脉修复患者中的5年预后。
背景:近期关于enduurant™内支架的研究主要是比较双模支架与其他制造商内支架的结果,或在制造商使用说明书(IFU)之外的病例的报告结果,而在制造商的IFU内对肾下腹主动脉瘤(AAA)进行标准血管内主动脉修复(EVAR)的数据比较双模支架与三模支架的经验有限。方法纳入标准:1)介入治疗前采用EndurantTM II (END II)或EndurantTM II (END II)支架在制造商的IFU 2)可用CTA内治疗的动脉瘤(直径> 50mm),并重建全主动脉1mm。比较两种装置的终点包括技术成功、30d死亡率、并发症发生率(转开腹修复出血、支架狭窄/闭塞、急性远端栓塞、感染或术后透析必要性)、内漏和再干预(5年随访)。比较基线介入前CTA和最后一次介入后CTA的动脉瘤囊直径。结果纳入100例接受END II (n=66)或END II (n=34)治疗的患者(90%为男性,平均年龄74岁)。技术成功率为99%。1例手术相关的活动性出血最终发生手术转换(END II n=1)。30d死亡率为0%。未出现初始I/III型内源性渗漏。19/100(19%)的患者需要再次干预(END II n=10;n=9, p= 0.17)。与END II/II相比,EVAR的结果包括技术成功率、30d死亡率、并发症发生率、内漏率和再干预率均无显著差异。结论:对于END II或II设备,EVAR的5年预后均显示出一致的安全有效结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信